{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=2&min-answer.questionFirstAnswered.=2024-04-30T11%3A36%3A16.753Z&uin=HL4654", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?houseId=2&min-answer.questionFirstAnswered.=2024-04-30T11%3A36%3A16.753Z&uin=HL4654", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=2&min-answer.questionFirstAnswered.=2024-04-30T11%3A36%3A16.753Z&uin=HL4654&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&houseId=2&min-answer.questionFirstAnswered.=2024-04-30T11%3A36%3A16.753Z&uin=HL4654", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=2&min-answer.questionFirstAnswered.=2024-04-30T11%3A36%3A16.753Z&uin=HL4654", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=2&min-answer.questionFirstAnswered.=2024-04-30T11%3A36%3A16.753Z&uin=HL4654", "items" : [{"_about" : "http://data.parliament.uk/resources/1718156", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1718156/answer", "answerText" : {"_value" : "<p>NHS England has successfully secured patient access to a number of innovative medicines under its policy of uniform pricing. European industry data from April 2023 showed that for every four treatments available in Europe, there is an additional medicine available in England, and a quarter more cancer drugs available in England compared to the European average.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Markham"}
        , "dateOfAnswer" : {"_value" : "2024-05-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-05-21T12:26:39.693Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-05-14", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs: Prices"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask His Majesty's Government what assessment they have made of the impact of the NHS England uniform pricing policy on patients' access to innovative medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1732", "label" : {"_value" : "Biography information for Lord Warner"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Warner"}
      ], "uin" : "HL4654"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}